United Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for United Therapeutics (UTHR).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

14Buy

1Hold

1Sell

Consensus RatingBuy# Analysts16Avg. Consensus PT$523Upside to Avg. PT-3.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	BTIG	Julian Harrison	Upgrade	Neutral→Buy	$728
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Initiate	Sell	$321
Aug 6, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$704→$677
Jul 23, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$685→$687
Jul 10, 2026	B of A Securities	Greg Harrison	PT Cut	Neutral	$620→$613
Jul 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$701→$704
May 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$707→$701
May 7, 2026	Wells Fargo	Benjamin Burnett	Upgrade	Equal-Weight→Overweight	$575→$738
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$471→$519
Mar 31, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$600→$660
Mar 31, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$486→$575
Mar 31, 2026	B of A Securities	Greg Harrison	PT Raise	Neutral	$569→$626
Mar 30, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$575→$660
Mar 23, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$466→$486
Mar 12, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	PT Raise	Overweight	$525→$625
Mar 5, 2026	UBS	Ashwani Verma	PT Raise	Buy	$655→$705
Feb 26, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$525→$600
Feb 26, 2026	TD Cowen	Joseph Thome	PT Raise	Buy	$525→$575
Feb 26, 2026	Oppenheimer	Andreas Argyrides	PT Raise	Outperform	$575→$600
Feb 26, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$587→$643

More with Benzinga EdgeGet Access

Analyst Ratings News

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.

Avi Kapoor

PRO
BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target

BTIG analyst Julian Harrison upgrades United Therapeutics (NASDAQ:UTHR) from Neutral to Buy and announces $728 price target.

Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321

Goldman Sachs analyst Andrea Newkirk initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Sell rating and announces Price Target of $321.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $685 to $687.

Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613

B of A Securities analyst Greg Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and lowers the price target from $620 to $613.

Benzinga Newsdesk

United Therapeutics Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

United Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PRO
BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target

PRO
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321

PRO
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

PRO
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687

PRO
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613

People Also Watch

People Also Watch

United Therapeutics Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

United Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PROBTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target

PROGoldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321

PRORBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

PROJP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687

PROB of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613

People Also Watch

People Also Watch

PRO
BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target

PRO
Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321

PRO
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677

PRO
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687

PRO
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613